Table 4.
Factors associated with receiving progestin therapy. (n = 4,007)
| Univariate |
p-value | Multivariable |
p-value | |||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||||
| Age at diagnosis, y | <.0001 | <.0001 | ||||||
| 40–45 | ||||||||
| <25 | 8.0 | 4.2 | 15.4 | 9.5 | 3.6 | 25.1 | ||
| 25–29 | 9.0 | 6.4 | 12.8 | 10.0 | 6.9 | 14.4 | ||
| 30–34 | 4.8 | 3.8 | 5.9 | 4.9 | 3.9 | 6.2 | ||
| 35–39 | 2.3 | 1.9 | 2.8 | 2.3 | 1.9 | 2.8 | ||
| Diagnosis Group | <.0001 | <.0001 | ||||||
| Endometrial | ||||||||
| Cancer | ||||||||
| Atypical | ||||||||
| Hyperplasia | 2.7 | 2.2 | 3.2 | 2.7 | 2.2 | 3.2 | ||
| Year of diagnosis | <.0001 | 0.0002 | ||||||
| 1999–2004 | ||||||||
| 2005–2008 | 1.5 | 1.0 | 2.0 | 1.0 | 0.7 | 1.4 | ||
| 2009–2014 | 2.2 | 1.6 | 3.0 | 1.5 | 1.1 | 2.0 | ||
| Region | 0.0194 | 0.0132 | ||||||
| South | ||||||||
| Northeast | 1.4 | 1.1 | 1.7 | 1.4 | 1.1 | 1.8 | ||
| North Central | 1.1 | 0.9 | 1.3 | 1.2 | 0.9 | 1.5 | ||
| West | 1.3 | 1.0 | 1.6 | 1.4 | 1.1 | 1.8 | ||
| Unknown | 1.2 | 0.7 | 2.0 | 1.4 | 0.8 | 2.4 | ||
| Insurance | 0.4756 | 0.6431 | ||||||
| HMO | ||||||||
| Other | 0.9 | 0.7 | 1.1 | 0.9 | 0.7 | 1.2 | ||
| PPO | 0.9 | 0.7 | 1.1 | 0.9 | 0.7 | 1.1 | ||
| Charlson Comorbidity Score | 0.2799 | 0.4077 | ||||||
| 0 | ||||||||
| 1 | 1.1 | 0.8 | 1.4 | 1.1 | 0.9 | 1.5 | ||
| ≥2 | 0.6 | 0.3 | 1.2 | 0.7 | 0.3 | 1.4 | ||
| Relationship to the Primary Beneficiary | <.0001 | 0.0112 | ||||||
| Employee | ||||||||
| Spouse | 0.8 | 0.6 | 0.9 | 0.8 | 0.6 | 0.9 | ||
| Child/Other | 2.6 | 1.4 | 5.1 | 0.9 | 0.3 | 2.5 | ||
a
P values are based on Wald test. Abbreviations: CI, confidence interval. OR, Odds ratio. HMO: health maintenance organization; PPO: preferred provider organization.